| |
Thursday, February 20, 2025 | 2pm ET / 11am PT Clinical trials only continue to increase in complexity. Join industry experts to explore how AI can transform workflows to help sponsors and CROs better manage data while maintaining speed, quality and compliance. Register now. 
|
|
Today’s Big NewsJan 28, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. Register now. 
|
|
| By Nick Paul Taylor BioAge Labs has given up on its lead obesity candidate. Weeks after stopping a trial in response to phase 2 data, the biotech has jettisoned the molecule and shifted its focus to a preclinical neuroinflammation prospect. |
|
|
|
By Gabrielle Masson Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small interfering RNA (siRNA) candidates in epilepsy and Huntington’s disease. |
By James Waldron Two months after launching Pep2Tango, VC firm Versant Ventures is unveiling another obesity-focused biotech in the form of Helicore Biopharma. |
Sponsored by Salesforce Drug development and commercialization leads to tremendous advances in medicine and improvements to everyday life, but it often comes at a cost. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now. 
|
|
By Darren Incorvaia Just days after President Trump imposed broad restrictions on communications, meetings, travel and public appearances at the Department of Health and Human Services (HHS), the National Institutes of Health (NIH) is clarifying the extent of the freeze’s effect. |
By Nick Paul Taylor Leap Therapeutics has come crashing down to earth. The biotech axed plans to advance into phase 3 in gastric cancer on the basis of midstage data, sending its stock down 60% to below $1, but it is forging ahead in another indication. |
By James Waldron Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of clinical data to show that the drug is less likely to be abused. |
By Gabrielle Masson Cell therapy biotech Aurion is moving forward with plans to IPO despite a pending lawsuit from one of its existing investors. |
By Darren Incorvaia After 20 years of building radioisotope expertise as a manufacturer and supplier, German firm ITM Isotope Technologies is ready to take center stage with drugs of its own. ITM’s lead radiopharmaceutical outperformed the current standard-of-care treatment at prolonging progression-free survival in a phase 3 trial in patients with inoperable neuroendocrine tumors, the company said. |
By James Waldron Takeda is taking back the home license for a phase 3-stage depression drug as part of an amendment to its multi-asset collaboration with Neurocrine. |
By Emma Beavins Healthcare organizations should review their DEI practices, lawyers said, and stay apprised of any enforcement actions on protecting single sex spaces. The private sector also has an opportunity to double down on its efforts to protect healthcare access, experts say. |
By Zoey Becker The company's board of directors unanimously rejected partner Biogen's $469 million buyout proposal, finding that it "significantly undervalues" the company and is not in the best interest of shareholders. |
By Conor Hale The FDA has tapped Sara Brenner to serve as acting commissioner as it awaits new leadership from the Trump administration to complete the congressional confirmation process. |
By Fraiser Kansteiner Activist Investor Starboard Value stopped short of nominating any directors to Pfizer’s board ahead of a Jan. 25 deadline, Bloomberg reported Monday. A Starboard-backed director—or two—would have given the investor more leverage as it attempts to influence Pfizer’s turnaround strategy. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of Intra-Cellular Therapies to former First Lady Jill Biden’s appearance at Fierce JPM Week. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
